What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?
Journal of The Association of Physicians of India · 2025
DOI: 10.59556/japi.73.1181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of The Association of Physicians of India, 2025. Verfasst von Deepak Talwar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Director and Chair Pulmonary Sleep & Critical Care Medicine, Metro Centre for Respiratory Diseases, WASOG Sarcoid Clinic, Noida, Uttar Pradesh, India…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pulmonary Disease, Chronic Obstructive, Ceftizoxime, Cefpodoxime. Die Arbeit nennt 40 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and pneumonia are challenging lower respiratory tract infections (LRTIs) commonly encountered in clinical practice. The oral extended-spectrum cephalosporin cefpodoxime proxetil is highly active against the bacterial pathogens commonly associated with LRTIs. AIM: To assess the role of cefpodoxime in the management of infections in Indian patients with AECOPD and LRTIs in a real-world setting, based on expert opinions. METHODOLOGY: The expert consensus meeting was convened according to an a priori protocol. Physicians were invited to participate in the discussion to frame opinion statements based on their clinical experience. A structured questionnaire was prepared regarding the role of cefpodoxime in the management of infections in patients with AECOPD and LRTIs. RESULTS: Streptococcus pneumoniae was the most common pathogen causing infections in patients with chronic bronchitis and pneumonia. Good penetration of cefpodoxime into lung tissues, high concentrations in lung tissues, and rapid resolution of symptoms make cefpodoxime the first-choice drug for treating LRTIs. Cefpodoxime is a step-down therapy of choice when switching hospitalized patients with LRTIs from parenteral antibiotics to oral antibiotics. Cefpodoxime is safe in patients with comorbid diseases and in elderly patients on polypharmacy. CONCLUSION: Cefpodoxime is the preferred first-line empiric antibiotic of choice for the treatment of community-acquired LRTIs in the real-world setting in India. Cefpodoxime has been preferred by 99% of expert chest physicians to treat infections in patients with chronic obstructive pulmonary disease (COPD), considering its broad spectrum of activity. Ninety-seven percent of experts reported that cefpodoxime, as a step-down therapy, gives satisfactory patient recovery and prevents recurrent infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Director and Chair Pulmonary Sleep & Critical Care Medicine, Metro Centre for Respiratory Diseases, WASOG Sarcoid Clinic, Noida, Uttar Pradesh, India, Corresponding Author.
- Chest Physician and Medical Director, Brahma Kumari's Global Hospital & Research Centre and Vora Clinic, Mumbai, Maharashtra, India, Orcid: https://orcid.org/0000-0002-9632-1807.
- Senior Consultant Interventional Pulmonologist & Sleep Disorder Specialist, Department of Pulmonology and Sleep Medicine, Apollo Hospitals, Hyderabad, Telangana, India.
- Professor and HOD, Department of Respiratory Medicine, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
- Professor and Head, Chest Medicine Department of Respiratory Medicine, Government Medical College Srinagar, Srinagar, Jammu and Kashmir, India, Orcid: https://orcid.org/0000-0002-9486-6715.
- Consultant Pulmonolgist, Founder and Director, Department of Pulmonology, Kalyan Hospital, Vadodara, Gujarat, India.
Zitieren
APA
Talwar, D., Vora, A., Tarke, C., Mehta, A., Shah, N. N., & Dalal, S. (2025). What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.73.1181
Vancouver
Talwar D, Vora A, Tarke C, Mehta A, Shah NN, Dalal S. What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?. Journal of The Association of Physicians of India. 2025. doi:10.59556/japi.73.1181
BibTeX
@article{Talwar2025,
author = {Talwar, Deepak and Vora, Agam and Tarke, Chandrakant and Mehta, Asmita and Shah, Naveed Nazir and Dalal, Sonia},
title = {What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?},
journal = {Journal of The Association of Physicians of India},
year = {2025},
doi = {10.59556/japi.73.1181}
}
EUVIMED